Английская Википедия:Bradanicline
Шаблон:Short description Шаблон:Drugbox
Bradanicline (INN,[1] code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder.[2] Phase I clinical trials were completed successfully, and it was in phase II trials.[3]
In May 2011, AstraZeneca declined to exercise its right to license the compound.[4] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.[5] It was being studied for cognitive and memory enhancement.[6]
Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late-2013.[7] It was also discontinued for ADHD.[7]
References
Шаблон:Nicotinic acetylcholine receptor modulators
Шаблон:Nervous-system-drug-stub
- Английская Википедия
- Antipsychotics
- Benzofuran-2-carboxamides
- Nicotinic agonists
- Drugs developed by AstraZeneca
- 3-Pyridyl compounds
- Quinuclidines
- Stimulants
- Abandoned drugs
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии
